GEN Exclusives

More »

GEN News Highlights

More »
Mar 25, 2008

Metabolon and the Harvard-Partners Healthcare Collaborate to Refine Warfarin Theranostic

  • Metabolon and the Harvard-Partners Healthcare Center for Genetics and Genomics (HPCGG) are working together to improve diagnostic tests related to warfarin dosing. The collaborators say that they will not only examine a patient’s genetics but also the metabolomic profile to determine the correct dosing regimen for this blood-thinning agent.

    Patient samples for the study are being collected as part of the ongoing HPCGG trial called Creating an Optimal Warfarin Nomogram (CROWN). It is a prospective dosing study that is focusing on genetic testing to determine the optimal warfarin dose. Sample collection for the diagnostic development should be complete in the summer. Metabolon will then conduct the metabolomic analysis.

    HPCGG investigators also have received preferred access to Metabolon's global biochemical profiling platform. These services provide for the extraction, identification, and quantitation of small molecules. The platform also highlights significantly altered metabolites related to these biochemicals.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?